Facioscapulohumeral muscular dystrophy

Facioscapulohumeral muscular dystrophy (FSHD or FSH) is characterised by muscle weakness that affects the muscles of the face, shoulders and arms and appears in adolescence or adulthood. This disease is due to a change in the structure of a small region of chromosome 4, the D4Z4 region.

 

Clinical trial ongoing at the Institute:

  • FIS-002-2019: Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)

 

Acronym

FIS-002-2019

Study type RIPH1
Intervention Losmapimod
Principal investigator
Teresinha Evangelista
Sponsor Fulcrum Therapeutics
Fundings Fulcrum Therapeutics
Study status
Ongoing
Recruitment status Ongoing
Population Adult
  + infos on clinicaltrials.gov